Latest FOLFOX Stories
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that VectibixÂ® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding...
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.
THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). Amgen believes that Vectibix in combination with chemotherapy provides an important...
THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(Â®) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorectal cancer...
Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival.
THOUSAND OAKS, Calif., Oct.
QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
Data Reported at ASCO Confirm a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
Phase 3 X-PECT Trial (Xeloda(R)) + Perifosine Evaluation in Colorectal Cancer Treatment) being conducted by partner Keryx Biopharmaceuticals pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, April 8 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
QUEBEC CITY, April 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- Large; stout; burly.